Isabel Guerra Merino-rekin lankidetzan egindako argitalpenak (18)

2023

  1. Post-mortem findings in Spanish patients with COVID-19; a special focus on superinfections

    Frontiers in Medicine, Vol. 10

  2. m6A levels and expression of its modification genes show significant differences in breast cancer molecular subtypes

    Genes and Diseases, Vol. 10, Núm. 5, pp. 1751-1754

  3. microRNA sequencing for biomarker detection in the diagnosis, classification and prognosis of Diffuse Large B Cell Lymphoma

    Scientific reports, Vol. 13, Núm. 1, pp. 12159

2022

  1. In silico identification and in vitro expression analysis of breast cancer-related m6A-SNPs

    Epigenetics, Vol. 17, Núm. 13, pp. 2144-2156

2021

  1. One-step nucleic acid amplification (Osna) of sentinel lymph node in early-stage endometrial cancer: Spanish multicenter study (endo-osna)

    Cancers, Vol. 13, Núm. 17

2020

  1. Miki (Mitotic Kinetics Regulator) Immunoexpression in Normal Liver, Cirrhotic Areas and Hepatocellular Carcinomas: a Preliminary Study with Clinical Relevance

    Pathology and Oncology Research, Vol. 26, Núm. 1, pp. 167-173

2018

  1. Brains with sporadic Creutzfeldt-Jakob disease and copathology showed a prolonged end-stage of disease

    Journal of Clinical Pathology, Vol. 71, Núm. 5, pp. 446-450

  2. Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report

    Cellular Oncology, Vol. 41, Núm. 2, pp. 213-221

2016

  1. Luminal B breast cancer subtype displays a dicotomic epigenetic pattern

    SpringerPlus, Vol. 5, Núm. 1

2014

  1. Huge Adrenal Hemorrhagic Endothelial Cyst Secondary to an Adrenal Arteriovenous Malformation and Mimicking a Malignant Lesion

    Endocrine Pathology

2013

  1. Disomy as the genetic underlying mechanisms of loss of heterozigosity in SDHD-paragangliomas

    Journal of Clinical Endocrinology and Metabolism, Vol. 98, Núm. 5

2010

  1. Breast and ovarian cancer risk evaluation in families with a disease-causing mutation in BRCA1/2

    Journal of Community Genetics, Vol. 1, Núm. 2, pp. 91-99

  2. LOH analysis should not be used as a tool to assess whether UVs of BRCA1/2 are pathogenic or not

    Familial Cancer

2007

  1. CHEK2 1100delC is present in familial breast cancer cases of the Basque Country [2]

    Breast Cancer Research and Treatment

  2. Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: Implications for genetic counselling

    Breast Cancer Research and Treatment, Vol. 106, Núm. 2, pp. 255-262

2006

  1. Chequeo de mutaciones en el gen BRCA1 en mujeres con cáncer de mama familiar y esporádico precoz, de la Comunidad Autónoma Vasca.

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 103, Núm. 1, pp. 9-12

2001

  1. Value of limited necropsy in HIV-positive patients

    Pathology Research and Practice, Vol. 197, Núm. 3, pp. 165-168

1991

  1. Carcinoma broncogénico primitivo doble sincrónico.

    Revista Clinica Espanola